Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
Sponsor: University of Michigan
A PHASE2 clinical study on Prostate Adenocarcinoma and Prostate Cancer, this trial is completed. The trial is conducted by University of Michigan and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Dec 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Mar 2021 — Apr 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Mar 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2018 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Michigan
For direct contact, visit the study record on ClinicalTrials.gov .